This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
by Zacks Equity Research
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
LQDANegative Net Change HROWNegative Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?
by Zacks Equity Research
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
JNJPositive Net Change LLYNegative Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
by Zacks Equity Research
BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.
BAYRYPositive Net Change LQDANegative Net Change IMCRPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
by Zacks Equity Research
RHHBY wins FDA priority review for Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer, with a decision due in October 2026.
RHHBYPositive Net Change LQDANegative Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
by Zacks Equity Research
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
GSKPositive Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
by Sundeep Ganoria
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change HRMYNegative Net Change
biotechs medical pharmaceuticals
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
by Sundeep Ganoria
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change HRMYNegative Net Change
biotechs medical pharmaceuticals
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
by Sundeep Ganoria
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
by Zacks Equity Research
Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.
SNYPositive Net Change LQDANegative Net Change KYMRPositive Net Change INDVPositive Net Change
biotechs
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care
by Zacks Equity Research
LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.
LLYNegative Net Change LQDANegative Net Change IMCRPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals